Maverick Therapeutics

What Maverick Therapeutics does

Maverick Therapeutics is a privately held biotechnology company founded in 2016 and headquartered in Brisbane, California. Per the company's stated positioning, it focuses on improving the lives of patients with solid tumor cancers, operating in the clinical-stage immuno-oncology space. The company develops T-cell based therapeutic approaches intended to redirect immune responses against solid tumor malignancies, an area with substantial unmet medical need where conventional therapies have had limited durability.

The company's business model is that of a venture-backed, clinical-stage biotech: it has no disclosed commercial revenue, no pricing model, and no product approvals in the source data. Its capital base was anchored by a single disclosed financing round in January 2017 of $125,000,000, with MPM Capital and Takeda as investors. The involvement of Takeda, a major global pharmaceutical company, as both an investor implies a strategic relationship that could support licensing, co-development, or acquisition pathways typical for solid tumor biotechs. There are no disclosed office locations, customer logos, distribution channels, partnerships, or management team entries in the provided data, and the Takeda Pharmaceuticals homepage content included in the aggregation pertains to Takeda rather than to Maverick Therapeutics specifically, limiting further detail.

Note: the input lists Maverick's headcount as "10,000+," which is inconsistent with a small private biotech founded in 2016 and most likely reflects a data quality issue inherited from a parent or sponsor record (likely Takeda). This figure has not been treated as reliable for Maverick's actual workforce.

Name

Maverick Therapeutics

Website

https://mavericktx.com

Company type

Private

Founded year

2016

Headcount range

5,001–10,000 employees

Short description

Maverick Therapeutics is a privately held, clinical-stage biotechnology company founded in 2016 in Brisbane, California, developing T-cell based immunotherapies for patients with solid tumor cancers.

Ownership category

akta.pro rank

Product category

Oncology Biologics / Immuno-Oncology Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

Keywords

• Cancer immunotherapy
• T-cell engagers
• Solid tumor therapeutics
• Bispecific antibodies
• Oncology biologics

Headquarters

HQ city

Brisbane

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Maverick Therapeutics develops T-cell engager-based immunotherapies for the treatment of solid tumor cancers. The company's pipeline is built around engineered bispecific antibodies designed to redirect patient T-cells to recognize and kill solid tumor cells, addressing cancers that have historically been resistant to conventional immuno-oncology agents.

Differentiator

Problem solved

Functional benefit

Products and services

• T-cell Engager Immunotherapy Pipeline (Maverick TCE Platform)

Ideal customer profiles2 records

Technology focussed Yes

API detail

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Expansion highlights2 records

Direct peers

• Adaptimmune Therapeutics: Clinical-stage biotech developing engineered TCR-based cell therapies for solid tumors. Highly comparable to Maverick given the shared focus on TCR redirection against solid tumor antigens.
• Harpoon Therapeutics: Developed T-cell engagers (TriTAC platform) targeting solid tumors; direct mechanistic peer to Maverick's T-cell engager approach for solid tumor malignancies.
• Macrogenics: Develops bispecific antibodies and T-cell engaging molecules for oncology, including solid tumor programs. Comparable modality and indication overlap with Maverick's solid tumor focus.

Emerging players

• Fate Therapeutics: Clinical-stage cell therapy company developing iPSC-derived NK and T-cell therapies for cancer. Adjacent to Maverick's TCR-based solid tumor approach within the broader cell-based immunotherapy category.
• Allogene Therapeutics: Allogeneic CAR-T developer for hematologic and solid tumor cancers. Comparable as a cell therapy platform targeting oncology, though focused on CAR-T rather than TCR engagers.
• Iovance Biotherapeutics: Leader in tumor-infiltrating lymphocyte (TIL) cell therapy for solid tumors. Closely related in the solid tumor cell therapy category that Maverick also targets.
• Precision BioSciences: Develops allogeneic CAR-T and in vivo gene editing therapies for oncology. Comparable as a clinical-stage cell/gene therapy peer pursuing solid tumor and hematologic indications.
• Cellectis: Clinical-stage gene-edited allogeneic CAR-T developer with solid tumor programs (e.g., UCART). Adjacent cell therapy platform peer in the immuno-oncology space.

Broad incumbents

• Takeda Pharmaceutical: Global pharmaceutical company and disclosed investor in Maverick. Operates a broad oncology portfolio including cell therapies and bispecifics, making it both a strategic backer and an incumbent comparable in the same therapeutic category.
• Bristol Myers Squibb: Global pharma with extensive solid tumor immunotherapy assets including Opdivo, Yervoy, and bispecific T-cell engagers. Represents the type of large incumbent that competes for the same solid tumor immunotherapy value Maverick targets.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks3 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Maverick Therapeutics